BACKGROUND: Tricyclic antidepressants (TCAs) are known to benefit subjects with functional nausea and vomiting (FNV), but it is not known if alternate neuromodulators are also beneficial. We retrospectively evaluated outcomes and clinical predictors of response in FNV subjects treated with any neuromodulator, including TCAs. METHODS: We identified 94 subjects (43.8±1.4 year, 79 F) with FNV (Rome III criteria) over a 12 year period, treated with neuromodulators and followed up for 8.5±1.1 months. Clinical presentation, demographics and gastric emptying study (GES) findings (when available) were extracted. Likert scales determined symptom severity at baseline and symptom response or remission at follow-up. Outcomes and predictors of response were evaluated using univariate and multivariate analyses. RESULTS: At least moderate symptom improvement was reported by 72.3%, and 22.3% had symptom remission. Proportions achieving moderate improvement and remission, and mean outcome Likert scores were similar regardless of neuromodulator agent used or GES status. On univariate and multivariate logistic regression analysis, baseline symptom severity affected symptom response, and pain negatively impacted symptom remission to treatment (p≤0.04 for each); GES status failed to predict treatment response or remission. CONCLUSIONS: Symptom improvement with neuromodulators may be seen in over two-thirds of subjects with FNV regardless of the specific agent administered. Response may be suboptimal in pain predominant presentations.
BACKGROUND: Tricyclic antidepressants (TCAs) are known to benefit subjects with functional nausea and vomiting (FNV), but it is not known if alternate neuromodulators are also beneficial. We retrospectively evaluated outcomes and clinical predictors of response in FNV subjects treated with any neuromodulator, including TCAs. METHODS: We identified 94 subjects (43.8±1.4 year, 79 F) with FNV (Rome III criteria) over a 12 year period, treated with neuromodulators and followed up for 8.5±1.1 months. Clinical presentation, demographics and gastric emptying study (GES) findings (when available) were extracted. Likert scales determined symptom severity at baseline and symptom response or remission at follow-up. Outcomes and predictors of response were evaluated using univariate and multivariate analyses. RESULTS: At least moderate symptom improvement was reported by 72.3%, and 22.3% had symptom remission. Proportions achieving moderate improvement and remission, and mean outcome Likert scores were similar regardless of neuromodulator agent used or GES status. On univariate and multivariate logistic regression analysis, baseline symptom severity affected symptom response, and pain negatively impacted symptom remission to treatment (p≤0.04 for each); GES status failed to predict treatment response or remission. CONCLUSIONS: Symptom improvement with neuromodulators may be seen in over two-thirds of subjects with FNV regardless of the specific agent administered. Response may be suboptimal in pain predominant presentations.
Authors: Henry P Parkman; Katherine Yates; William L Hasler; Linda Nguyen; Pankaj J Pasricha; William J Snape; Gianrico Farrugia; Kenneth L Koch; Jorge Calles; Thomas L Abell; Richard W McCallum; Linda Lee; Aynur Unalp-Arida; James Tonascia; Frank Hamilton Journal: Clin Gastroenterol Hepatol Date: 2011-08-24 Impact factor: 11.382
Authors: Douglas A Drossman; Brenda B Toner; William E Whitehead; Nicholas E Diamant; Chris B Dalton; Susan Duncan; Shelagh Emmott; Valerie Proffitt; Donna Akman; Karen Frusciante; Terry Le; Kim Meyer; Barbara Bradshaw; Kristi Mikula; Carolyn B Morris; Carlar J Blackman; Yuming Hu; Huanguang Jia; Jim Z Li; Gary G Koch; Shrikant I Bangdiwala Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: Heba N Iskandar; Benjamin Cassell; Navya Kanuri; C Prakash Gyawali; Alexandra Gutierrez; Themistocles Dassopoulos; Matthew A Ciorba; Gregory S Sayuk Journal: J Clin Gastroenterol Date: 2014 May-Jun Impact factor: 3.062
Authors: David R Spiegel; Alexander Pattison; Alexis Lyons; Umer Ansari; Aidan L Mccroskey; Eric Luehrs; Lauren Barr; Stephanie Le Journal: Innov Clin Neurosci Date: 2017-06-01